Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-30T19:08:23.806Z Has data issue: false hasContentIssue false

P01-101 - Unique: Assessing the Efficacy of Quetiapine Fumarate Augmentation of SSRI or SNRI Treatment in SSRI- or SNRI-resistant Major Depressive Disorder

Published online by Cambridge University Press:  17 April 2020

J. Lejeune
Affiliation:
Centre Hospitalier Regional ‘La Citadelle’, Liege
C. Taeter
Affiliation:
AstraZeneca Belgium
V. Duquenne
Affiliation:
AstraZeneca Belgium
N. Goodman
Affiliation:
Harrison Clinical Research, Brussels, Belgium

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives

The UNIQUE study assessed the effect of Quetiapine fumarate augmentation on the overall depression status of patients with major depressive disorder and who did not respond to any acute treatment with selective serotonin reuptake inhibitors (SSRIs) or selective noradrenalin reuptake inhibitors (SNRIs) and naïve to any atypical antipsychotics.

Methods

Between March 2006 and November 2007, 39 male and female patients, aged 18-65, were enrolled into this four-week, open label, non-comparative, multicentric, phase II prospective study. Treatment with Quetiapine fumarate began at enrolment, with a titration to a target dose of 300mg. The following scales were completed during all five visits: Montgomery-Asberg Depression Rating Scale (MADRS); Clinical Global Impression (CGI); Brief Psychiatric Rating Scale (BPRS); Sheehan Disability Scale (SDS).

Results

All questionnaire mean scales were significantly reduced (Friedman P< 0.0001) at the end of the study from baseline: MADRS 16.9 (12.8-21.0); CGI 1.94 (1.52-2.37); BPRS 10.3 (6.7-13.6); SDS 8.5 (5.6-11.5). Response, defined as a reduction in MADRS total score >50% was observed in 45.9% of the 37 patients completing at least 2 weeks of the study and 37.8% were considered in remission e.g. MADRS total score ≤ 12 at visit 5.

Conclusions

Quetiapine fumarate augmentation improved the overall depression status of patients resistant to SSRI or SNRI treatment.

Type
Affective disorders / Unipolar depression / Bipolar disorder
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.